This study systematically expounds, analyzes the experience of medical insurance access for new indications of drugs in five typical countries with international expert interview, literature review, including Japan, South Korea, the Netherlands, France, Switzerland. Based on the international experience, this study puts forward suggestions on national medical insurance access process, payment standard for new indications application in China
Key words
innovative drugs /
new indications application /
national medical insurance access /
payment standards /
international experience
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 李轶,丁锦希,李伟,等.多适应症药物准入支付标准测算模式研究[J].中国医疗保险,2021,(10):41-46.
[2] 张宸,凡馨,金秋晨,等.日本儿童药定价及价格激励政策对我国的启示[J].中国药房,2021,32(23):2822-2827.
[3] MASANOBU YAMATE. Update of Drug Pricing System in Japan[EB/OL].(2021-3-20)[2022-10-07] .https://www.pmda.go.jp/files/000221888.pdf.
[4] KWON, H Y., GODMAN, B.Drug Pricing in South Korea. Appl Health Econ Health Policy[J]. ,2017,15: 447-453.
[5] 伍琳,陈永法.韩国和德国专利药价格谈判模式比较研究及启示[J].中国卫生政策研究, 2015, 8(10): 62-67.
[6] LAWLOR R,WILSDON T, DARQUENNES E, et al.Accelerating patient access to oncology medicines with multiple indications in Europe[J].Mark Access Health Policy, 2021, 9(1): 196.
[7] FRANKEN M, KOOPMANSCHAP M, STEENHOEK A.Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?[J]. Z Evid Fortbild Qual Gesundhwes, 2014, 108(7): 383-9.
[8] ZORGINSTITUUT NEDERLAND. Sluis voor dure geneesmiddelen[EB/OL].(2018-7-1)[2022-10-07] https://www.zorginstituutnederland.nl/over-ons/programmas-en-samenwerkingsverbanden/horizonscan-geneesmiddelen/sluis-voor-dure-geneesmiddelen.
[9] National Authority for health France. Pricing & Reimbursement of drugs and HTA policies in France[EB/OL].(2014-3-14)[2022-10-07] https://www.has-sante.fr/upload/docs/application/pdf/2014-03/pricing_reimbursement_of_drugs_and_hta_policies_in_france.pdf.
[10] JACQUET E, KEROUANI-LAFAYE G, GRUDE F, et al. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years[J]. Eur J Cancer.2021 May;149:82-90.
[11] 孙利华,李世琪,范嘉宁.创新药阈值及其医保支付模式探讨[J].中国医疗保险,2022(08):53-55.
[12] 刘昭,张帆,向贵圆,等.基于风险管理的创新药支付准入案例分析及实施建议[J].中国医疗保险,2022(04):22-27.
[13] 孙利华,范嘉宁.基于价值的多适应症药品医保准入模式探讨[J].中国医疗保险,2022(07):53-56.
[14] 陈静. 医保谈判下的创新药机会[J].理财周刊,2021(11):32.
[15] 王美凤,王海银,丛鹂萱,等.台湾地区创新药医保支付方式经验及启示研究[J].世界临床药物,2021,42(03):223-228.
[16] 鲁全,苏泽瑞,王琬.医疗保障制度对本土创新药发展的支持政策研究[J].中国卫生政策研究,2020,13(06):1-7.
[17] 范长生,赵蒙蒙,谢洋,等.关于医保谈判药品价值评估和支付标准形成的若干探讨[J].中国医疗保险,2020(11):73-77.
